%0 Journal Article
%A Castro-Espin, Carlota
%A Cairat, Manon
%A Navionis, Anne-Sophie
%A Dahm, Christina C
%A Antoniussen, Christian S
%A Tjønneland, Anne
%A Mellemkjær, Lene
%A Mancini, Francesca Romana
%A Hajji-Louati, Mariem
%A Severi, Gianluca
%A Le Cornet, Charlotte
%A Kaaks, Rudolf
%A Schulze, Matthias B
%A Masala, Giovanna
%A Agnoli, Claudia
%A Sacerdote, Carlotta
%A Crous-Bou, Marta
%A Sanchez-Perez, Maria-Jose
%A Amiano, Pilar
%A Chirlaque, María-Dolores
%A Guevara, Marcela
%A Smith-Byrne, Karl
%A Heath, Alicia K
%A Christakoudi, Sofia
%A Gunter, Marc J
%A Rinaldi, Sabina
%A Agudo, Antonio
%A Dossus, Laure
%T Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
%D 2024
%@ 1532-1827
%U https://hdl.handle.net/10668/24322
%X Background: Inflammation influences tumour progression and cancer prognosis, but its role preceding breast cancer (BC) and its prognostic implications remain inconclusive.Methods: We studied pre-diagnostic plasma inflammatory biomarkers in 1538 women with BC from the EPIC study. Cox proportional hazards models assessed their relationship with all-cause and BC-specific mortality, adjusting for tumour characteristics and lifestyle factors.Results: Over a 7-year follow-up after diagnosis, 229 women died, 163 from BC. Elevated IL-6 levels were associated with increased all-cause mortality risk (HR1-SD 1.25, 95% CI 1.07-1.47). Among postmenopausal, IL-6 was associated with higher all-cause (HR1-SD 1.41, 95% CI 1.18-1.69) and BC-specific mortality (HR1-SD 1.31, 95% CI 1.03-1.66), (PHeterogeneity (pre/postmenopausal) < 0.05 for both), while IL-10 and TNFα were associated with all-cause mortality only (HR1-SD 1.19, 95% CI 1.02-1.40 and HR1-SD 1.28, 95% CI 1.06-1.56). Among ER+PR+, IL-10 was associated with all-cause and BC-specific mortality (HR1-SD 1.35, 95% CI 1.10-1.65 and HR1-SD 1.42 95% CI 1.08-1.86), while TNF-α was associated with all-cause mortality in HER2- (HR1-SD 1.31, 95% CI 1.07-1.61). An inflammatory score predicted higher all-cause mortality, especially in postmenopausal women (HR1-SD 1.30, 95% CI 1.07-1.58).Conclusions: Higher pre-diagnosis IL-6 levels suggest poorer long-term survival among BC survivors. In postmenopausal survivors, elevated IL-6, IL-10, and TNFα and inflammatory scores seem to predict all-cause mortality.
%K Biomarkers
%K Breast neoplasms
%K Cohort studies
%K Diagnosis
%K Inflammation
%K Interleukin-10
%K Interleukin-6
%K Life Style
%K Methods
%K Mortality
%~